UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients

Hypertension (Dallas, Tex. 1979), 2015-08, Vol.66 (2), p.368-373

2015

Link zum Volltext

Verfügbarkeit prüfen

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

The Lancet (British edition), 2021-09, Vol.398 (10305), p.1053-1064

2021

Link zum Volltext

Verfügbarkeit prüfen

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension

JAMA : the journal of the American Medical Association, 2006-09, Vol.296 (10), p.1242

2006

Link zum Volltext

Verfügbarkeit prüfen

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-03, Vol.45 (5), p.712-719

2005

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-02, Vol.45 (2), p.198-202

2005

Link zum Volltext

Verfügbarkeit prüfen

Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy

Journal of hypertension, 2015-12, Vol.33 (12), p.2422-2430

2015

Link zum Volltext

Verfügbarkeit prüfen

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death the life study

Circulation (New York, N.Y.), 2007-08, Vol.116 (7), p.700-705

2007

Link zum Volltext

Verfügbarkeit prüfen

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2002-09, Vol.20 (9), p.1879-1886

2002

Link zum Volltext

Verfügbarkeit prüfen

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Annals of internal medicine, 2003-12, Vol.139 (11), p.901

2003

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation : The losartan intervention for end point reduction in hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-03, Vol.45 (5), p.705-711

2005

Link zum Volltext

Verfügbarkeit prüfen

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study

Journal of hypertension, 2006-04, Vol.24 (4), p.775-781

2006

Link zum Volltext

Verfügbarkeit prüfen

Eligibility for Renal Denervation: Experience at 11 European Expert Centers

Hypertension (Dallas, Tex. 1979), 2014-06, Vol.63 (6), p.1319-1325

2014

Link zum Volltext

Verfügbarkeit prüfen

Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2012-08, Vol.60 (2), p.347-353

2012

Link zum Volltext

Verfügbarkeit prüfen

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Journal of hypertension, 2004-09, Vol.22 (9), p.1805-1811

2004

Link zum Volltext

Verfügbarkeit prüfen

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Link zum Volltext

Verfügbarkeit prüfen

Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study

American journal of hypertension, 2012-10, Vol.25 (10), p.1101-1109

2012

Link zum Volltext

Verfügbarkeit prüfen

Serum Uric Acid Is Associated With New-Onset Diabetes in Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Study

American journal of hypertension, 2010-08, Vol.23 (8), p.845-851

2010

Link zum Volltext

Verfügbarkeit prüfen

Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study

Journal of hypertension, 2002-03, Vol.20 (3), p.405-412

2002

Link zum Volltext

Verfügbarkeit prüfen

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy

Journal of hypertension, 2006-08, Vol.24 (8), p.1531-1539

2006

Link zum Volltext

Verfügbarkeit prüfen

Incomplete Remission with Short-Term Prednisolone Treatment in Collagenous Colitis: a Randomized Study

Scandinavian journal of gastroenterology, 2003-01, Vol.38 (6), p.606-610

2003

Link zum Volltext

Verfügbarkeit prüfen

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2009-03, Vol.27 (3), p.567-574

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Journal of hypertension, 2005-04, Vol.23 (4), p.891-898

2005

Link zum Volltext

Verfügbarkeit prüfen

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy : The LIFE (losartan intervention for endpoint reduction in hypertension) study

Circulation (New York, N.Y.), 2005-04, Vol.111 (15), p.1924-1931

2005

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk: A LIFE Substudy

Hypertension (Dallas, Tex. 1979), 2005-09, Vol.46 (3), p.492-499

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(27)
Life Sciences & Biomedicine
(27)
Middle Aged
(27)
Science & Technology
(27)
Female
(25)
Male
(25)
Cardiovascular System & Cardiology
(23)
Hypertension - Drug Therapy
(22)
Peripheral Vascular Disease
(20)
Losartan - Therapeutic Use
(19)
Atenolol - Therapeutic Use
(18)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Antihypertensive Agents - Therapeutic Use
(17)
Cardiology. Vascular System
(16)
Hypertension
(16)
Medicin Och Hälsovetenskap
(16)
Aged, 80 And Over
(15)
Risk Factors
(15)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death the life study

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation : The losartan intervention for end point reduction in hypertension (LIFE) study

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study

Eligibility for Renal Denervation: Experience at 11 European Expert Centers

Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study

Serum Uric Acid Is Associated With New-Onset Diabetes in Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Study

Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy

Incomplete Remission with Short-Term Prednisolone Treatment in Collagenous Colitis: a Randomized Study

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy : The LIFE (losartan intervention for endpoint reduction in hypertension) study

Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk: A LIFE Substudy

Aktive Filter

Suchergebnisse filtern